title: Health and economic impact of rotavirus vaccination in GAVI-eligible countries.
abstract: BACKGROUND
  Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries.
  
  
  METHODS
  We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios.
  
  
  RESULTS
  Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 55% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (approximately $5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (approximately 94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population.
  
  
  CONCLUSIONS
  Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.
authors.affiliation: Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA. sykim@hsph.harvard.edu
authors.forename: Sun-Young
authors.initials: SY
authors.lastname: Kim
authors.forename: Steve
authors.initials: S
authors.lastname: Sweet
authors.forename: David
authors.initials: D
authors.lastname: Slichter
authors.forename: Sue J
authors.initials: SJ
authors.lastname: Goldie
mesh_terms: D003362:Cost-Benefit Analysis; D003906:Developing Countries; D005102:Health Expenditures; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D007223:Infant; D011159:Population Surveillance; D019057:Quality-Adjusted Life Years; D012400:Rotavirus Infections / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000191:economics*
chemical_list: D022243:Rotavirus Vaccines
references.citation: Med Decis Making. 2010 Sep-Oct;30(5):E1-E28
references.pmid: 20729510
references.citation: Wkly Epidemiol Rec. 2008 Nov 21;83(47):421-5
references.pmid: 19024780
references.citation: Value Health. 2008 Dec;11(7):1081-7
references.pmid: 19602214
references.citation: J Infect Dis. 2005 Nov 15;192(10):1720-6
references.pmid: 16235169
references.citation: Bull World Health Organ. 2008 Jan;86(1):27-39
references.pmid: 18235887
references.citation: Vaccine. 2007 Dec 17;25(52):8851-60
references.pmid: 18022735
references.citation: Pharmacoeconomics. 2008;26(3):191-215
references.pmid: 18282015
references.citation: BMC Infect Dis. 2008 Jul 29;8:103
references.pmid: 18664280
references.citation: Rev Panam Salud Publica. 2008 Apr;23(4):221-30
references.pmid: 18505602
references.citation: Vaccine. 2009 Jun 19;27(30):4025-30
references.pmid: 19389452
references.citation: J Infect Dis. 2009 Nov 1;200 Suppl 1:S9-S15
references.pmid: 19817620
references.citation: J Infect Dis. 2009 Nov 1;200 Suppl 1:S195-202
references.pmid: 19817600
references.citation: J Virol. 2006 Nov;80(21):10724-33
references.pmid: 16928744
references.citation: Med Decis Making. 2007 Mar-Apr;27(2):128-37
references.pmid: 17409363
references.citation: Emerg Infect Dis. 2003 May;9(5):565-72
references.pmid: 12737740
references.citation: Educ Health (Abingdon). 2003 Jul;16(2):230
references.pmid: 14741909
references.citation: Pediatr Ann. 2006 Jan;35(1):23-8
references.pmid: 16466072
references.citation: J Infect Dis. 2005 Sep 1;192 Suppl 1:S133-45
references.pmid: 16088797
references.citation: Lancet. 2008 Apr 5;371(9619):1181-9
references.pmid: 18395579
references.citation: Rev Panam Salud Publica. 2009 Jun;25(6):481-90
references.pmid: 19695142
references.citation: J Infect Dis. 2009 Nov 1;200 Suppl 1:S114-24
references.pmid: 19817591
references.citation: J Infect Dis. 2009 Nov 1;200 Suppl 1:S28-38
references.pmid: 19817610
references.citation: Rev Panam Salud Publica. 2007 Apr;21(4):205-16
references.pmid: 17612464
references.citation: Rev Med Virol. 2005 Jan-Feb;15(1):29-56
references.pmid: 15484186
references.citation: Science. 2009 Jul 17;325(5938):290-4
references.pmid: 19608910
references.citation: Vaccine. 2007 May 16;25(20):3971-9
references.pmid: 17400341
references.citation: Vaccine. 2009 Oct 19;27(44):6121-8
references.pmid: 19715781
references.citation: Cost Eff Resour Alloc. 2006 Aug 21;4:14
references.pmid: 16923181
references.citation: N Engl J Med. 2006 Jan 5;354(1):11-22
references.pmid: 16394298
references.citation: Pharmacoeconomics. 2008;26(6):477-95
references.pmid: 18489199
references.citation: Vaccine. 2008 Jul 29;26(32):4080-93
references.pmid: 18550229
references.citation: Vaccine. 2007 Apr 20;25(16):3137-41
references.pmid: 17321017
references.citation: N Engl J Med. 2009 Nov 12;361(20):1919-21
references.pmid: 19907040
references.citation: Health Policy Plan. 2007 May;22(3):178-85
references.pmid: 17412742
references.citation: J Infect Dis. 2009 Nov 1;200 Suppl 1:S85-91
references.pmid: 19817619
references.citation: J Health Popul Nutr. 2008 Dec;26(4):388-96
references.pmid: 19069617
references.citation: J Infect Dis. 2009 Nov 1;200 Suppl 1:S76-84
references.pmid: 19817618
references.citation: J Infect Dis. 2009 Nov 1;200 Suppl 1:S70-5
references.pmid: 19817617
references.citation: Vaccine. 2007 Jan 4;25(2):373-80
references.pmid: 16930784
references.citation: BMJ. 2009 Sep 25;339:b3653
references.pmid: 19783581
references.citation: J Infect Dis. 2009 Nov 1;200 Suppl 1:S92-8
references.pmid: 19817621
references.citation: J Med Virol. 2007 Jul;79(7):1009-16
references.pmid: 17516525
references.citation: Vaccine. 2008 Jan 30;26(5):706-15
references.pmid: 18166250
references.citation: Value Health. 2007 Sep-Oct;10(5):336-47
references.pmid: 17888098
references.citation: Pediatrics. 2007 Apr;119(4):684-97
references.pmid: 17403839
references.citation: J Infect Dis. 2009 Nov 1;200 Suppl 1:S154-9
references.pmid: 19817594
references.citation: Wkly Epidemiol Rec. 2009 Jun 5;84(23):220-36
references.pmid: 19499606
references.citation: BMC Public Health. 2009 Jan 21;9:29
references.pmid: 19159483
references.citation: Epidemiol Infect. 2008 Jan;136(1):44-55
references.pmid: 17335631
references.citation: Clin Infect Dis. 2009 Oct 15;49(8):1202-10
references.pmid: 19739973
references.citation: J Infect Dis. 2009 Nov 1;200 Suppl 1:S16-27
references.pmid: 19817595
references.citation: Bull World Health Organ. 2003;81(3):197-204
references.pmid: 12764516